What factors determine patients' preference for tumour necrosis factor inhibitors in ankylosing spondylitis?

Clinical Rheumatology

Volumn 28, Issue 5, 2009, Pages 599-602

  Fajri, Dessy W ^a   Brand, Caroline A ^b,c   Dharmage, Shyamali C ^d   Martin, Belinda J ^a   Buchanan, Russell R C ^a   Schachna, Lionel ^a  

^a AUSTIN HEALTH   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Ankylosing spondylitis; Choice; Determinants; Intravenous; Preference; Subcutaneous; Tumour necrosis factor inhibitor

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; CONTROLLED STUDY; DRUG CHOICE; DRUG COST; DRUG PREFERENCE; FEMALE; HOME CARE; HUMAN; LEISURE; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PATIENT DECISION MAKING; PATIENT SATISFACTION; PRIORITY JOURNAL;

ADULT; ANTIRHEUMATIC AGENTS; COMMUNICATION; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PATIENT SATISFACTION; QUESTIONNAIRES; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 64449088699     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-009-1104-4     Document Type: Article

References (14)

1. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, Gromnica-Ihle E, Kellner H, Krause A, Schneider M, Sorensen H, Zeidler H, Thriene W, Sieper J (2002) Treatment of active ankylosing spondylitis with infliximab: A randomised controlled multicentre trial. Lancet 359:1187-1193
2. Braun J, Sieper J (2007) Ankylosing spondylitis. Lancet 369:1379-1390
3. Burr ML, Sinnathurai P, Ginawi A, Ostor AJ (2007) Route of administration of biologic therapy: What do patients prefer? Arthritis Rheum 56(suppl):S473
4. Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, Jenkinson T (1994) A new approach to defining functional ability in ankylosing spondylitis: The development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21:2281-2285
5. Coulter A, Entwistle V, Gilbert D (1999) Sharing decisions with patients: Is the information good enough? BMJ 318:318-322
6. Davis JC Jr, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, Kivitz A, Fleischmann R, Inman R, Tsuji W (2003) Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: A randomized, controlled trial. Arthritis Rheum 48:3230-3236
7. DeWitt EM, Glick HA, Albert DA, Joffe MM, Wolfe F (2006) Medicare coverage of tumor necrosis factor alpha inhibitors as an influence on physicians' prescribing behavior. Arch Intern Med 166:57-63
8. Doward LC, Spoorenberg A, Cook SA, Whalley D, Helliwell PS, Kay LJ, McKenna SP, Tennant A, van der Heijde D, Chamberlain MA (2003) Development of the ASQoL: A quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis 62:20-26
9. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: The Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21:2286-2291
10. Jones SD, Steiner A, Garrett SL, Calin A (1996) The Bath Ankylosing Spondylitis Patient Global Score (BAS-G). Br J Rheumatol 35:66-71
11. Say RE, Thomson R (2003) The importance of patient preferences in treatment decisions-challenges for doctors. BMJ 327:542-545
12. van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, Dougados M, Reveille JD, Wong RL, Kupper H, Davis JC Jr (2006) Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 54:2136-2146
13. van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27:361-368
14. Williams EL, Edwards CJ (2006) Patient preferences in choosing anti-TNF therapies. Rheumatology 45:1575-1576